Oncology

Lenalidomide found to prevent the formation of blood vessels that feed tumors, yet carries significant adverse effects.

Gilteritinib (Xospata, Astellas Pharma) is indicated for adults with relapsed/refractory acute myeloid leukemia with an FMS-like tyrosine kinase 3 mutation.

A ‘fail-first’ policy by the Centers for Medicare and Medicaid Services could be a nightmare for patients with cancer, according to the Community Oncology Alliance.

Many patients with pancreatic cancer do not receive cancer-directed treatment that may extend survival.

Top news of the day from across the health care landscape.

Genomic data may improve the selection of more precise models for metastatic breast cancer research.

National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice is the first nationwide precision oncology trail for patients with cancers that have not responded to standard treatments.

Officials with the FDA have approved alpelisib (Piqray, Novartis) tablets, to be used in combination with the endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

Using real-time data helped providers identify racial disparities in cancer treatment and narrow the gap in treatment completion rates between white and black patients.

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut, explains the role of genomics in prostate cancer.

Study suggests future interventions targeting improvements in cancer screenings may need to focus on the time of day when a patient visits a doctor.

Top news of the week from Specialty Pharmacy Times.

The oncology pharmaceutical market is rapidly growing and changing.

What can health systems do to provide a seamless journey during a time of uncertainty?

Technological advancements empower patients to manage their own health.

All stakeholders in the health care continuum should always remember that there is a person at the end of their businesses who depends on them to survive and have a high quality of life.

On February 6, 2019, the Department of Health and Human Services (HHS) proposed a rebate rule, Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.

If you want to be a player in specialty pharmacy, oncology is the place to be.

Welcome to the ninth annual Specialty Pharmacy Times oncology issue, in which we focus on the challenges and progress associated with treating cancer in the specialty space.

An analysis showed short-term health plans can expose enrollees to significant out-of-pocket costs for serious illnesses, such as cancer.

Study explored a novel drug’s efficacy in overcoming ibrutinib-resistant mantle cell lymphoma.

Top news of the day from across the health care landscape.

The approval of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) offers an additional option for adults with previously-untreated chronic lymphocytic leukemia.

The FDA’s Oncology Drugs Advisory Committee challenged the results of the phase 3 QuANTUM-R study.

Avelumab (Bavencio) plus axitinib (Inlyta) is indicated for the first-line treatment of patients with advanced renal cell carcinoma.

Procedure uses small incisions and a miniature video camera to reduce the risk of complications from surgery for lung cancer.

Kaposi sarcoma is a cancer caused by an associated herpesvirus that develops from the cells that line lymph or blood vessels, and most commonly affects individuals with HIV.

Pomalidomide (Pomalyst, Celgene) showed clinical benefit in patients with Kaposi sarcoma, regardless of HIV status.

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut, discusses recent key trials involving non-metastatic castrate-resistant prostate cancer.

From 2018 to 2040, the number of patients who will need chemotherapy each year is estimated to rise from 9.8 million to 15 million.